Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CAP-1002 passes safety review
September 2019
SHARING OPTIONS:

LOS ANGELES—Capricor Therapeutics Inc.'s Phase 2 HOPE-2 study of CAP-1002 got the green light to continue, as the company's independent data and safety monitoring board completed its safety assessment and futility analysis review of the study and recommended that the study continue. This trial—a randomized, double-blind, placebo-controlled clinical trial—is evaluating CAP-1002 in boys and young men with advanced Duchenne muscular dystrophy (DMD). Participants receive either CAP-1002 or placebo via IV every three months. Capricor's therapy consists of allogeneic cardiosphere-derived cells, a type of progenitor cell shown to exert potent immuno-modulatory activity and thought to modify the immune system to stimulate cellular regeneration. Thus far, CAP-1002 has received RMAT and orphan drug designation from the FDA for treating DMD.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.